6th International AIDS Conference


San Francisco, California, USA — June 20-23, 1990

Print this Article


Response to hepatitis B vaccination in HIV seropositive patients.

Int Conf AIDS 1990 Jun 20-23; 6:334 (abstract no. 1082)
Ramirez V, Garcia S, Romero J, Jover J; Servicio Regional de Salud. Comunidad Autonoma de Madrid. Spain.

OBJECTIVE: To evaluate the response to Hepatitis B vaccination in HIV seropositive patients.

METHODS: Ninety-one individuals negative for Hepatitis B virus markers (HBsAg, HBcAc, HBsAc) were recruited from patients attending a sexual transmission disease clinic. They were divided into 2 groups: 40 HIV seropositive and 51 HIV seronegative subjects (as a control group). Both recruited a similar rate of subjects with risk practices (homosexual men, IV drug users and HIV positive partners) ranged from 17 to 57 years and distributed by sex (77,5% of males in the HIV seropositive group and 74,4% in the control group). Global response to Hepatitis B vaccination was studied for the variables of age and sex in both group. Also seroconversion and median response (10 UI/1 less than or equal to HBsAc less than or equal to 100 UI/l) or high response (HBsAc greater than 100 UI/l). Both groups were stratified in two groups of age (less than 30 years and greater than or equal to 30 years), fixing also sex variable. Hepatitis B and HIV markers were screened by ELISA. Recombinant DNA vaccine was used and given at 0.1.6 months with evaluation one month after the last dose. Statistical Analysis: Comparison of proportion independent samples, Mc Nemar test and binomial distribution for signification test.

RESULTS: Differences in seroconversion between case (65%) and control group (92%) are significant (p=0,0061). Differences in seroconversion between males from both groups are significant (p=0,0077), but not among females. Considering age (ranged in two groups: less than 30 and greater than or equal to 30 years) seroconversion showed to be higher in the control group (p=0,0021). Response (high or median) was better in the control group (p=0,032).

CONCLUSIONS: Hepatitis B vaccination in HIV seropositive individuals seems to have low response. Post-vaccination controls are desirable in HIV seropositive vaccinated patients in order to evaluate seroconversion and the need of booster doses.

Keywords: AEGIS, HIV Seropositivity, Hepatitis B Vaccines, Hepatitis B, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Hepatitis B Virus, HIV Infections, Homosexuality, Substance Abuse, Intravenous, Hepatitis B Core Antigens, Vaccination, Vaccines, DNA, Human, Male, Female, ICA6

900620
1082

Copyright © 1990 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.